Ushbu ma'lumotlar faqat ta'lim maqsadida taqdim etilgan. U tibbiy maslahat sifatida mo'ljallanmagan. Har doim malakali tibbiyot mutaxassisiga murojaat qiling.
Tavsif, Dozalash, Nojo'ya ta'sirlar, Qarshi ko'rsatmalar. Data from EMA, URPL, openFDA and other regulatory sources.
| Metronidazole | Clindamycin | |
|---|---|---|
| Faol moddalar | METRONIDAZOLE | CLINDAMYCIN PHOSPHATE |
| ATC kodi | A01AB17 | D10AF01 |
| Dori shakli | CAPSULE | INJECTION, SOLUTION |
| Dozalash | 375MG | 150 mg/mL |
| Qo'llash usuli | ORAL | INTRAMUSCULAR, INTRAVENOUS |
| Ishlab chiqaruvchi | PFIZER INC | Sagent Pharmaceuticals |
Metronidazole (INN: METRONIDAZOLE, ATC A01AB17) and Clindamycin (INN: CLINDAMYCIN PHOSPHATE, ATC D10AF01) differ in active substance, indications, and safety profile. The table above summarizes the clinical differences from regulatory documents.
Combination safety depends on mechanisms and your health profile. Use our interactions checker and always consult your doctor or pharmacist before combining medications.
Both drugs are approved when used per label. Safety is patient-specific — the better choice depends on your condition, other medications, allergies, and comorbidities. Consult a healthcare professional for personalized advice.
Ushbu ma'lumotlar faqat ta'lim maqsadida taqdim etilgan. U tibbiy maslahat sifatida mo'ljallanmagan. Har doim malakali tibbiyot mutaxassisiga murojaat qiling.